INTRODUCTION: The administration of biologic disease-modifying antirheumatic drugs, including tumor necrosis factor (TNF)-α inhibitors, is observed to interfere with the disease activity and progression. In this study, we aimed to assess the effectiveness and response predictors of adalimumab (ADA), a TNF-α blocker, in patients with axial spondyloarthritis (AxSpA). METHODS: This study was a historical prospective, registry-based observational study on patients with AxSpA treated with first-line ADA after conventional drug failure. For evaluation and comparison, patients were divided into three groups according to the number of years from AxSpA diagnosis to initiation of ADA treatment: (A) <5 years, (B) 5-10 years, and (C) >10 years. The assessment instruments ankylosing spondylitis disease activity score (ASDAS), Bath ankylosing spondylitis activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), health assessment questionnaire (HAQ), Short Form 36 questionnaire (SF-36), and EuroQoL 5 dimension questionnaire (EQ-5D) were regularly administered for up to 24 months of follow-up. RESULTS: This study included 1043 patients with AxSpA (9.2% with non-radiographic AxSpA, 68.9% men). By month 6, a significantly higher proportion of patients with ASDAS remission (<1.3) was achieved upon earlier intervention in group A (30.1%) and B (32.9%) than in the late intervention group C (22.6%) (p ⩽ 0.05). At month 6, lower age and better BASFI at treatment initiation were identified as the strongest predictors of ASDAS remission in both univariable [odds ratio (OR): 0.956, p ⩽ 0.001; OR: 0.834, p ⩽ 0.001, respectively] and multivariable analyses (OR: 0.963, p ⩽ 0.001; OR: 0.859, p ⩽ 0.001, respectively). Earlier intervention also led to improvement in most patient-reported outcomes (PROs) based on HAQ, SF-36, and EQ-5D. CONCLUSION: Results from the ATTRA registry concur with previous clinical trials that supported efficacy of TNF-α blockers and showed better treatment outcomes with early interventions, including reduction of disease activity and improvement in PROs. We identified age and BASFI as the main factors influencing treatment effectiveness.

Department of Pediatric and Adult Rheumatology Motol University Hospital 5 Úvalu 84 Prague 150 06 Czech Republic

Department of Pediatric and Adult Rheumatology Motol University Hospital Prague Czech Republic

Institute of Biostatistics and Analyses Ltd [a spinoff company of Masaryk University] Brno Czech Republic

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Davis JC, Jr, van der Heijde D, Braun J, et al.. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–3236. PubMed

Inman RD, Davis JC, Jr, van der Heijde D, et al.. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402–3412. PubMed

Landewé R, Braun J, Deodhar A, et al.. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73: 39–47. PubMed PMC

Maxwell LJ, Zochling J, Boonen A, et al.. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015; 14: CD005468. PubMed PMC

van der Heijde D, Dijkmans B, Geusens P, et al.. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582–591. PubMed

van der Heijde D, Kivitz A, Schiff MH, et al.. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136–2146. PubMed

Haibel H, Rudwaleit M, Listing J, et al.. Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58: 1981–1991. PubMed

Sieper J, van der Heijde D, Dougados M, et al.. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72: 815–822. PubMed PMC

van der Heijde D, Schiff MH, Sieper J, et al.. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922–929. PubMed PMC

Davis JC, Jr, Revicki D, van der Heijde DM, et al.. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 2007; 57: 1050–1057. PubMed

López-Medina C, Garrido-Castro JL, Castro-Jiménez J, et al.. Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. Clin Rheumatol 2018; 37: 1581–1588. PubMed

van der Heijde D, Breban M, Halter D, et al.. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford) 2015; 54: 1210–1219. PubMed PMC

Akkoc N, Can G, D’Angelo S, et al.. Therapies of early, advanced, and late onset forms of axial spondyloarthritis, and the need for treat to target strategies. Curr Rheumatol Rep 2017; 19: 8. PubMed

Baraliakos X, Gensler LS, D’Angelo S, et al.. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20906040. PubMed PMC

Poddubnyy D, Listing J, Haibel H, et al.. Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Rheumatology 2018; 57: 703–711. PubMed

Danve A, Deodhar A. Treat to target in axial spondyloarthritis: what are the issues. Curr Rheumatol Rep 2017; 19: 22. PubMed

Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology 2020; 59: iv79–iv89. PubMed PMC

Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 2014; 16: 109. PubMed PMC

Dubash S, McGonagle D, Marzo-Ortega H. New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Ther Adv Chronic Dis 2018; 9: 77–87. PubMed PMC

Furst DE, Louie JS. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther 2019; 21: 135. PubMed PMC

Mease P. Emerging immunomodulatory therapies and new treatment paradigms for axial spondyloarthritis. Curr Rheumatol Rep 2019; 21: 35. PubMed

Rudwaleit M, Schwarzlose S, Hilgert ES, et al.. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008; 67: 1276–1281. PubMed

Sieper J, Lenaerts J, Wollenhaupt J, et al.. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014; 73: 101–107. PubMed PMC

Song I-H, Althoff CE, Haibel H, et al.. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012; 71: 1212–1215. PubMed

Molto A, López-Medina C, van den Bosch FE, et al.. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis 2021; 80: 1436–1444. PubMed PMC

Haroon N, Inman RD, Learch TJ, et al.. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65: 2645–2654. PubMed PMC

Jones GT, Dean LE, Pathan E, et al.. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials. Ann Rheum Dis 2020; 79: 914–919. PubMed

Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Ther Adv Musculoskelet Dis 2018; 10: 129–139. PubMed PMC

Machado P, Landewé R, Lie E, et al.. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70: 47–53. PubMed

Garrett S, Jenkinson T, Kennedy LG, et al.. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–2291. PubMed

Calin A, Garrett S, Whitelock H, et al.. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–2285. PubMed

Balestroni G, Bertolotti G. L’EuroQol-5D (EQ-5D): uno strumento per la misura della qualità della vita [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis 2012; 78: 155–159. PubMed

Klein JP, Logan B, Harhoff M, et al.. Analyzing survival curves at a fixed point in time. Stat Med 2007; 26: 4505–4519. PubMed

Aletaha D, Maa J-F, Chen S, et al.. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2019; 78: 1609–1615. PubMed PMC

Carron P, Varkas G, Renson T, et al.. High rate of drug-free remission after induction therapy with golimumab in early peripheral spondyloarthritis. Arthritis Rheumatol 2018; 70: 1769–1777. PubMed

Coates LC, Moverley AR, McParland L, et al.. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015; 386: 2489–2498. PubMed PMC

Grigor C, Capell H, Stirling A, et al.. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–269. PubMed

Davis JC, Dougados M, Braun J, et al.. Definition of disease duration in ankylosing spondylitis: reassessing the concept. Ann Rheum Dis 2006; 65: 1518–1520. PubMed PMC

Feldtkeller E, Erlendsson J. Definition of disease duration in ankylosing spondylitis. Rheumatol Int 2008; 28: 693–696. PubMed

Barkham N, Keen HI, Coates LC, et al.. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60: 946–954. PubMed

Song IH, Hermann K, Haibel H, et al.. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70: 590–596. PubMed PMC

Dougados M, van der Heijde D, Tsai WC, et al.. Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study. Health Qual Life Outcomes 2020; 18: 4. PubMed PMC

Imkamp M, Lima Passos V, Boonen A, et al.. Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open 2018; 4: e000755. PubMed PMC

Macfarlane GJ, Rotariu O, Jones GT, et al.. Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). Ann Rheum Dis 2020; 79: 202–208. PubMed

Mease PJ, Heijde DV, Karki C, et al.. Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based Corrona Registry. Arthritis Care Res (Hoboken) 2018; 70: 1661–1670. PubMed PMC

Rudwaleit M, Claudepierre P, Wordsworth P, et al.. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36: 801–808. PubMed

Sieper J, Landewé R, Magrey M, et al.. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open 2019; 5: e000917. PubMed PMC

Vastesaeger N, van der Heijde D, Inman RD, et al.. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011; 70: 973–981. PubMed PMC

Glintborg B, Sørensen IJ, Østergaard M, et al.. Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An observational cohort study from the nationwide DANBIO registry. J Rheumatol 2017; 44: 59–69. PubMed

Macfarlane GJ, Pathan E, Jones GT, et al.. Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology 2020; 59: 2481–2490. PubMed PMC

Arends S, van der Veer E, Kamps FB, et al.. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol 2015; 33: 174–180. PubMed

Rudwaleit M, Listing J, Brandt J, et al.. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665–670. PubMed PMC

Machado PM, Deodhar A. Treat-to-target in axial spondyloarthritis: gold standard or fools’ gold? Curr Opin Rheumatol 2019; 31: 344–348. PubMed

Arends S, Brouwer E, van der Veer E, et al.. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94. PubMed PMC

Poddubnyy D, Sieper J. Treatment of axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep 2020; 22: 47. PubMed PMC